Core Viewpoint - The company announced a delay in the completion of its "Escitalopram Oxalate API Production Project" due to construction challenges, but this will not materially affect its main business or fundraising plans [1] Group 1: Project Investment and Funding - The company plans to invest 53.50 million yuan in the production project, funded by proceeds from its initial public offering [1] - The project aims to enhance the production capacity of active pharmaceutical ingredients [1] Group 2: Project Delay and Impact - The timeline for the project’s operational status has been postponed from February 23, 2026, to June 30, 2026, due to existing infrastructure issues affecting construction [1] - The delay does not involve changes to the project’s implementation entity, construction content, investment scale, or funding usage [1] - The company emphasizes that the delay will not impact its overall strategic goals and aims to improve the efficiency of fundraising utilization [1] Group 3: Project Management - The company will continue to strengthen project management to ensure timely completion of the construction [1]
西点药业：部分募集资金投资项目延期